Cantor Fitzgerald Starts Durect Corp (DRRX) at Overweight

Cantor Fitzgerald analyst Elemer Piros initiates coverage on Durect Corp (NASDAQ: DRRX) with an Overweight rating and a price target of $5.00.

The analyst commented, "DURECT has an investigational pipeline centered on epigenetic regulators, as well as an enhanced drug delivery platform. The stock value has nearly tripled over the last three months, primarily due to initial compelling data in alcoholic hepatitis (AH) and a licensing agreement for DURECT's SABER technology with Gilead (GILD - OW, covered by A. Young). Numerous catalysts remain in 2019, in our view, including: 1) additional AH data, 2) initial NASH and psoriasis data, and 3) the user fee decision related to POSIMIR for post-operative pain. We have high conviction on DURECT's pipeline and expect trials to read out positively."

For an analyst ratings summary and ratings history on Durect Corp click here. For more ratings news on Durect Corp click here.

Shares of Durect Corp closed at $1.66 yesterday.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy